Biotech Values

[genisi]

making cross-trial comparisons even harder

So a bit more on this: the FOLFIRINOX regimen phase 3 was a randomized trial while the Abraxane/Gemzar phase 1/2 was an uncontrolled trial. Big difference. Don't know about patient selection there. For example, I'd think that patients with metastatic disease might not react as strongly as those with locally advanced disease to Abraxane/Gemzar treatment.
We are yet to see if tox profile associated with the double treatment also holds (by also I mean in addition to efficacy parameters especially OS) in the bigger randomized phase 3 trial.